New Hope in Cancer Treatment for Dogs: PharmaCom BioVet’s Veterinary Oncology Treatment Centers

Raleigh, NC, March 03, 2009 --(PR.com)-- The recently established PharmaCom BioVet Inc. (PINKSHEETS: PHMB) is making headway in opening the nation’s first branded Veterinary Oncology Treatment Centers dedicated for the care of animals and has continued to expand, giving hope to dog lovers dealing with the many forms of canine cancer.

Millions of Americans count their beloved dogs among their family members. Love for four-legged, family companions runs deep, as does the stress when animals face serious illnesses. A diagnosis of cancer causes fear and even deeper worry for most families, and the anguish of enduring a pet’s suffering and loss of the animal is tragic.

How does the family dog get treated for cancer, and how effective are any of the available treatments? Questions about the animals comfort, quality of life and prognosis for longevity are uppermost.

Recent strides in diagnostics, surgical techniques, cancer-targeting drugs, as well as radiation therapy and alternative treatments have made for more successful detection and remedies for companion dogs.

Under the management of Steve A. York, Vice President Operations and Marketing and Gary S. Berthold, President and Chief Executive Officer, PharmaCom BioVet Inc. has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer to have a greater life expectancy and decreased pain.

They plan treatment centers across the U.S., starting with its flagship Missouri center.

Co-founder and management team member, Sharon Berthold, Executive Vice President of PharmaCom BioVet, Inc., stated: “Plans are underway to build and fully staff PharmaCom BioVet’s first treatment center with some of the nation’s top veterinary oncologists. The company also plans to collaborate with partner firms, which are also located at Monsanto Place [in St. Louis County, Mo.], to offer specialized care for companion animals suffering from all forms of cancer.”

The foundation of PharmaCom BioVet rests on the heartfelt loss experienced by Gary and Sharon Berthold:

“We lost three of our Siberian Huskies, who were our close family members, to cancer,” Gary Berthold said, adding that he and his wife tried to find treatments other than “30-year-old chemotherapy.”

When no readily available or practical solutions were found, the Bertholds vowed: “We would spend the rest of our lives for the sake of our living dogs — in addition to all other dogs — attempting to find better, improved cancer treatments.”

The couple was encouraged because there were some promising, state-of-the-art alternatives under development, but stated knowingly, “Somebody has to get the ball rolling.”

So they founded their company to conduct the necessary research, development and testing in order to bring canine cancer treatment devices and formulas to market.

Despite the trend, which shows a marked increase in spending by families on veterinary medications, products and services to improve pets’ lives, there lacks much corporate motivation for major pharmaceutical companies to explore this area of pet healthcare. Even though some cancer treatment drugs were animal tested before human trials, drugs in use for humans may not provide satisfactory results in canines.

Although the veterinary industry revenue is increasingly promising, that alone does not create enough incentive for major drug firms to shift from their traditional human-consumption drug selling with the mega-profits it yields; therefore, there remains a void in animal cancer treatment drugs. Filling the need for better canine cancer screening, therapy and alternative treatment is PharmaCom BioVet’s sole focus.

The interest in the marketplace and the apparent need, along with the Berthold’s personal commitment to succeed in helping companion animals, provides the opportunity and incentive for PharmaCom BioVet to grow its company and its line of products, treatments and animal care facilities nationwide.

“We will begin treating companion animals that have cancer, specifically canines at this time, and then plan to treat felines in the future,” Gary Berthold stated.

“We certainly hope our treatments will provide a better quality of life to companion animals with cancer, in addition to the possibility of increasing lifespan. Of course, every situation is different…” he added.

PharmaCom BioVet Inc. has announced its collaborative relationships with two other companies: IsoTherapeutics Group LLC and PetScreen Ltd. to, respectively, (1) explore new breakthroughs in direct injection liquid brachytherapy therapeutic radioisotope procedures into cancerous tumors and (2) provide blood testing screening for lymphoma to achieve better diagnosis and monitoring of companion animals with that form of cancer.

The Berthold’s and Steve York’s collective decades of experience and education in business, veterinary sciences, biology, animal care, marketing, construction and business management make them a formidable team capable of bringing their plans to fruition.

Recently, celebrities who have been hearing about the activities of PharmaCom BioVet have started to endorse the company. Celebrity endorsements, as well as the TV commercial the company plans to air, are available at www.youtube.com/pharmacombiovet for viewing.

Visit their website at www.pharmacombiovet.com to find out why they are truly “a union of compassion and technology.”

###